12/28
08:12 pm
otlk
Third Time's The Charm: Outlook Therapeutics Lytenava Heads To FDA, Again [Seeking Alpha]
Low
Report
Third Time's The Charm: Outlook Therapeutics Lytenava Heads To FDA, Again [Seeking Alpha]
12/26
07:07 pm
otlk
Outlook Therapeutics Announces New Employment Inducement Grants [Yahoo! Finance]
Low
Report
Outlook Therapeutics Announces New Employment Inducement Grants [Yahoo! Finance]
12/26
05:00 pm
otlk
Outlook Therapeutics Announces New Employment Inducement Grants
Low
Report
Outlook Therapeutics Announces New Employment Inducement Grants
12/22
08:02 am
otlk
Oncobiologics (NASDAQ:OTLK) had its price target raised by analysts at Ascendiant Capital Markets from $8.00 to $10.00. They now have a "buy" rating on the stock.
Medium
Report
Oncobiologics (NASDAQ:OTLK) had its price target raised by analysts at Ascendiant Capital Markets from $8.00 to $10.00. They now have a "buy" rating on the stock.
12/19
08:35 am
otlk
Outlook Therapeutics Reports Financial Results for Fiscal Year 2025 [Yahoo! Finance]
Medium
Report
Outlook Therapeutics Reports Financial Results for Fiscal Year 2025 [Yahoo! Finance]
12/19
08:05 am
otlk
Outlook Therapeutics Reports Financial Results for Fiscal Year 2025
Medium
Report
Outlook Therapeutics Reports Financial Results for Fiscal Year 2025
12/10
04:10 am
otlk
Oncobiologics (NASDAQ:OTLK) had its "sell (d-)" rating reaffirmed by analysts at
Weiss Ratings.
Neutral
Report
Oncobiologics (NASDAQ:OTLK) had its "sell (d-)" rating reaffirmed by analysts at
Weiss Ratings.
12/3
04:32 pm
otlk
Oncobiologics (NASDAQ:OTLK) had its "sell (d-)" rating reaffirmed by analysts at
Weiss Ratings.
Medium
Report
Oncobiologics (NASDAQ:OTLK) had its "sell (d-)" rating reaffirmed by analysts at
Weiss Ratings.
11/24
09:05 am
otlk
Outlook Therapeutics to Present at the Piper Sandler 37th Annual Healthcare Conference
Medium
Report
Outlook Therapeutics to Present at the Piper Sandler 37th Annual Healthcare Conference
11/21
02:04 pm
otlk
Oncobiologics (NASDAQ:OTLK) had its "sell (e+)" rating reaffirmed by analysts at
Weiss Ratings.
Medium
Report
Oncobiologics (NASDAQ:OTLK) had its "sell (e+)" rating reaffirmed by analysts at
Weiss Ratings.
11/13
08:30 am
otlk
Outlook Therapeutics Announces Acceptance of Biologics License Application by U.S. FDA for ONS-5010 as a Treatment for Wet AMD
Medium
Report
Outlook Therapeutics Announces Acceptance of Biologics License Application by U.S. FDA for ONS-5010 as a Treatment for Wet AMD
11/3
08:35 am
otlk
Outlook Therapeutics Re-Submits Biologics License Application for ONS-5010
Neutral
Report
Outlook Therapeutics Re-Submits Biologics License Application for ONS-5010
10/31
01:04 pm
otlk
Oncobiologics (NASDAQ:OTLK) had its "sell (d-)" rating reaffirmed by analysts at
Weiss Ratings.
Low
Report
Oncobiologics (NASDAQ:OTLK) had its "sell (d-)" rating reaffirmed by analysts at
Weiss Ratings.
9/30
08:05 am
otlk
Oncobiologics (NASDAQ:OTLK) had its "neutral" rating reaffirmed by analysts at HC Wainwright. They now have a $1.00 price target on the stock.
Medium
Report
Oncobiologics (NASDAQ:OTLK) had its "neutral" rating reaffirmed by analysts at HC Wainwright. They now have a $1.00 price target on the stock.